DelveInsight’s Acute Myeloid Leukemia market report thoroughly explains the Acute Myeloid Leukemia, historical and forecasted epidemiology, as well as the Acute Myeloid Leukemia market trends in the 7MM. The report also proffers an analysis of the current Acute Myeloid Leukemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs.
Some of the Key Highlights from Acute Myeloid Leukemia Market Report
Have queries? Request for the sample @ Acute Myeloid Leukemia Market Research
Acute Myeloid Leukemia: Overview
Acute Myeloid Leukemia (AML), also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia, is a type of hematologic cancer characterized by clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and other tissues. AML can affect tissues other than bone marrow and blood, such as lymph nodes, the brain, skin, etc.
Acute Myeloid Leukemia Epidemiology Segmentation
The Acute Myeloid Leukemia report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Acute Myeloid Leukemia Treatment Landscape
Most AML patients are treated with two chemotherapy (chemo) phases: remission induction (also known as induction) and consolidation (postremission therapy). APL is a subtype of AML that is treated differently. Because AML can progress rapidly, treatment should usually begin as soon as possible after diagnosis.
Acute Myeloid Leukemia Market Outlook
According to DelveInsight’s analysts, the market is expected to grow positively during the forecast period (2018–2030), owing primarily to increased incidence and the anticipated launch of novel therapies such as ASTX727 Dociparstat Sodium, Pevonedistat, CPI-613, and others.
Acute Myeloid Leukemia Pipeline Therapies and Key Companies
Learn more about the emerging therapies and companies @ Acute Myeloid Leukemia Pipeline Therapies
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Acute Myeloid Leukemia (AML) Market Overview at a Glance
4.
Executive Summary of Acute Myeloid Leukemia (AML)
5.
Disease Background and Overview
6.
Epidemiology and Patient Population
7.
Organizations contributing towards Acute Myeloid Leukemia (AML)
8.
Case Reports
9.
Patient Journey
10.
Marketed Therapies
11.
Emerging Therapies
12.
Other Promising Therapies
13.
Acute Myeloid Leukemia (AML): 7 Major Market Analysis
14.
Market Drivers
15.
Market Barriers
16.
SWOT Analysis
17.
Unmet Needs
18.
Market Access
19.
KOL Views
20.
Appendix
21.
DelveInsight Capabilities
22.
Disclaimer
23.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Related Reports
Chronic Phase Chronic Myeloid Leukemia Market
DelveInsight’s “Chronic Phase Chronic Myeloid Leukemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Phase Chronic Myeloid Leukemia, historical and forecasted epidemiology, as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the 7MM.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/